Palbociclib

CAS: 571190-30-2

Palbociclib, a new breast cancer drug developed by Pfizer in the United States, is

marketed as IBRANCE, an oral cyclin-dependent kinase (CDKs) 4 and 6 inhibitor,

the first cyclin-dependent kinase 4/6 (cdk4/6) inhibitor approved by the us FDA.

CDKs4 and 6 are key regulators of cell cycle and can trigger cell cycle progression.

IBRANCE is indicated in the United States for the combination of letrozole for the

treatment of estrogen receptor-positive, and human epidermal growth factor receptor-negative

(ER+/ her2-negative) postmenopausal advanced breast cancer patients, as an initial

endocrine-based regimen for the treatment of metastatic diseases.

We can customize according to customer’s requirement

if you have any question pls mail us or call us